A Study to Investigate LYL797 in Adults With Solid Tumors Read more about A Study to Investigate LYL797 in Adults With Solid Tumors
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial Read more about Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials Read more about Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
A Study of PF-07260437 in Advanced or Metastatic Solid Tumors Read more about A Study of PF-07260437 in Advanced or Metastatic Solid Tumors
A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors Read more about A Clinical Study of Intravenous T3011 Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Read more about Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.
To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer Read more about To Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer Read more about Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Read more about Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
FPA150 in Patients With Advanced Solid Tumors Read more about FPA150 in Patients With Advanced Solid Tumors